$48.92▴ 1.18%
End-of-day close · 2026-09-01
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
Not enough data yet
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
Not enough data yet
Not enough revenue history to measure growth.
Leverage
Not enough data yet
More coming: dilution / share-count creep.
Fair value
Overvalued
Trading about 34% above our fair-value range
A cash-flow (DCF) estimate cross-checked against peer multiples.
✦ The read
AtriCure, Inc.'s earnings-quality signal is not available yet.
Key numbers
Recent news
Atrial Fibrillation Treatment Devices Market Trends and Forecast, 2035 | Includes Profiles of Abbott, AtriCure, Boston Scientific, Johnson & Johnson, and Medtronic
Two AtriCure Directors Trimmed Shares After a Strong Quarter. Here's What Matters for Investors- AtriCure (ATRC) Advances Key Heart Disease Trial 12 Months Ahead of Schedule